Canadian (TSX) Biotech Industry Analysis

Industry Valuation and Performance

Has the Canadian Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 05 Jul 2026	CA$2.8b	CA$91.3m	-CA$267,890,805.21	1.5x	-10.5x	30.7x
Tue, 02 Jun 2026	CA$3.1b	CA$91.0m	-CA$264,180,252.36	19.2x	-11.6x	33.6x
Thu, 30 Apr 2026	CA$2.8b	CA$88.5m	-CA$246,766,466.13	52.3x	-11.2x	31.3x
Sat, 28 Mar 2026	CA$2.5b	CA$90.5m	-CA$249,549,950.64	48.6x	-10x	27.6x
Mon, 23 Feb 2026	CA$3.0b	CA$93.7m	-CA$238,497,970.51	21.6x	-12.4x	31.5x
Wed, 21 Jan 2026	CA$2.8b	CA$95.7m	-CA$243,535,310.30	22.1x	-11.7x	29.7x
Fri, 19 Dec 2025	CA$2.4b	CA$95.3m	-CA$239,647,675.71	23x	-10x	25.2x
Sun, 16 Nov 2025	CA$2.3b	CA$95.2m	-CA$230,516,213.97	23.6x	-9.9x	23.9x
Tue, 14 Oct 2025	CA$2.2b	CA$95.7m	-CA$226,334,342.23	23.8x	-9.5x	22.6x
Thu, 11 Sep 2025	CA$1.7b	CA$95.6m	-CA$221,799,170.71	26.9x	-7.5x	17.4x
Sat, 09 Aug 2025	CA$1.6b	CA$91.2m	-CA$216,145,904.89	22.1x	-7.4x	17.5x
Mon, 07 Jul 2025	CA$1.6b	CA$91.0m	-CA$270,282,688.79	23.2x	-6x	17.8x
Wed, 04 Jun 2025	CA$1.5b	CA$90.7m	-CA$304,124,529.54	24.2x	-4.9x	16.5x
Fri, 02 May 2025	CA$1.4b	CA$92.9m	-CA$284,653,535.16	19.8x	-5x	15.4x
Sun, 30 Mar 2025	CA$1.5b	CA$85.7m	-CA$299,402,992.27	21.7x	-5x	17.6x
Tue, 25 Feb 2025	CA$1.6b	CA$88.6m	-CA$316,571,532.03	25.8x	-5.2x	18.6x
Thu, 23 Jan 2025	CA$1.6b	CA$87.5m	-CA$318,470,114.16	25.7x	-5x	18.2x
Sat, 21 Dec 2024	CA$1.5b	CA$85.5m	-CA$330,832,238.08	15.4x	-4.4x	17x
Mon, 18 Nov 2024	CA$1.3b	CA$83.3m	-CA$248,916,369.03	8.4x	-5x	15x
Wed, 16 Oct 2024	CA$1.3b	CA$80.4m	-CA$279,861,924.14	9x	-4.7x	16.4x
Fri, 13 Sep 2024	CA$963.5m	CA$80.3m	-CA$282,226,551.49	9.3x	-3.4x	12x
Sun, 11 Aug 2024	CA$1.1b	CA$76.1m	-CA$325,799,137.96	11.1x	-3.4x	14.4x
Tue, 09 Jul 2024	CA$1.1b	CA$76.1m	-CA$335,992,838.27	10.6x	-3.4x	15x
Thu, 06 Jun 2024	CA$1.2b	CA$76.8m	-CA$341,934,985.26	11.5x	-3.5x	15.6x
Sat, 04 May 2024	CA$910.7m	CA$78.8m	-CA$301,427,806.57	12.4x	-3x	11.6x
Mon, 01 Apr 2024	CA$1.1b	CA$88.1m	-CA$313,609,280.42	11.1x	-3.6x	12.8x
Wed, 28 Feb 2024	CA$1.2b	CA$93.1m	-CA$321,110,511.25	10.7x	-3.7x	12.6x
Fri, 26 Jan 2024	CA$3.6b	CA$86.3m	-CA$516,847,901.00	7x	-6.9x	41.2x
Sun, 24 Dec 2023	CA$3.6b	CA$86.1m	-CA$521,808,413.00	6.9x	-6.9x	41.7x
Tue, 21 Nov 2023	CA$3.8b	CA$86.7m	-CA$545,015,515.00	5.5x	-7x	44.3x
Thu, 19 Oct 2023	CA$3.8b	CA$89.0m	-CA$532,660,477.00	5.2x	-7.1x	42.6x
Sat, 16 Sep 2023	CA$3.9b	CA$87.3m	-CA$510,039,702.00	6.2x	-7.7x	45.2x
Mon, 14 Aug 2023	CA$4.0b	CA$85.8m	-CA$523,486,994.00	6.9x	-7.6x	46.3x
Wed, 12 Jul 2023	CA$4.1b	CA$81.5m	-CA$516,969,587.00	13.2x	-7.9x	50.3x

Current Industry PE

Investors are optimistic on the Canadian Biotechs industry, and appear confident in long term growth rates.

The industry's 3-year average PS ratio of 24.2x is exceeded by the industry's current PS ratio of 30.5x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have improved over the last three years.
Revenues for these companies have grown 3.8% per year.
This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?


CA Market	0.99%
Healthcare	3.42%
Biotech	3.02%
Biotech	3.02%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
DRUG Bright Minds Biosciences	CA$95.29	6.4% +CA$55.9m	164.2%	PB3x
MSCL Satellos Bioscience	CA$10.91	7.0% +CA$14.8m	49.0%	PB2.3x
EPRX Eupraxia Pharmaceuticals	CA$9.53	1.6% +CA$9.8m	24.7%	PB4.1x
PAIN Vector Science and Therapeutics	CA$2.43	2.1% +CA$7.7m	n/a	PB152x
ATLE Atlas Energy	CA$0.15	5.2% +CA$4.7m	-39.0%	PB3.7x

Company

Last Price

Valuation

DRUG Bright Minds Biosciences

CA$95.29

6.4%
+CA$55.9m

164.2%

PB3x

MSCL Satellos Bioscience

CA$10.91

7.0%
+CA$14.8m

49.0%

PB2.3x

EPRX Eupraxia Pharmaceuticals

CA$9.53

1.6%
+CA$9.8m

24.7%

PB4.1x

PAIN Vector Science and Therapeutics

CA$2.43

2.1%
+CA$7.7m

n/a

PB152x

ATLE Atlas Energy

CA$0.15

5.2%
+CA$4.7m

-39.0%

PB3.7x

Atlas Energy Corp. Announces Appointments to Subsidiary Board

Atlas Energy Corp. announced that Patrick Drouin and Dion Degrand will be appointed to the board of directors of Atlas Energy International SEZC, the Company’s Cayman Islands subsidiary, subject to receipt of applicable Cayman Islands regulatory approvals. Patrick Drouin is the President of Wheaton Precious Metals International and Chief Sustainability Officer for the Wheaton group. Before being appointed President in October 2023, Mr. Drouin was the Senior Vice President of Sustainability & Investor Relations at Wheaton Precious Metals, an executive role primarily responsible for the company’s sustainability efforts and engaging with the investment community. Prior to Wheaton, Mr. Drouin worked for UBS Securities from 2001 to 2012 in institutional equity sales across North America and Europe, most recently in London as Head of European Sales for UBS Canada. In this role, Mr. Drouin built a sales platform responsible for advising fund managers on Canadian equities. Throughout his advisory career, he has focused on the resource sector. Prior to UBS, he served as a Project Geologist in the San Francisco Bay Area for William Lettis & Associates. Mr. Drouin has an MBA from the Rotman School of Management, University of Toronto, and a Masters in Geology from the University of Memphis. Dion Degrand is the Chief Executive Officer of the Rawlinson & Hunter group of companies in the Cayman Islands, providing a full range of professional services including fiduciary, trust and corporate, fund governance and administration, accounting, restructuring and compliance services to international clients. Mr. Degrand has over 30 years of experience across investment banking, public and private capital markets, accounting, international banking, and independent governance. Prior to relocating to the Cayman Islands, Mr. Degrand spent the majority of his career in oil and gas investment banking, holding senior positions at leading investment banks, including Head of Canadian Energy at Raymond James (Canada), Head of Energy and Head of Western Canada at Cormark Securities, Managing Director at National Bank Financial and Principal at Peters & Co. Limited. Mr. Degrand is a CA, CPA and CFA charterholder, and a CIMA-registered director under the Cayman Islands Directors Registration and Licensing Act.

Canadian (TSX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

New major risk - Financial position

Insufficient new directors

Vector Science and Therapeutics Files Patent for Wearable Transdermal Peptide Delivery Platform

We're Not Very Worried About Bright Minds Biosciences' (CSE:DRUG) Cash Burn Rate

New major risk - Revenue and earnings growth

Satellos Bioscience Inc. Receives FDA Fast Track Designation For SAT-3247 For The Treatment Of Duchenne Muscular Dystrophy

New major risk - Revenue and earnings growth

New major risk - Financial position

Atlas Energy Corp. Announces Appointments to Subsidiary Board

New minor risk - Share price stability

Cosciens Biopharma Inc. Announces Appointment of Peter H. Puccetti as President, Effective June 18, 2026

Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors

New major risk - Financial position

New major risk - Financial position

Covalon Technologies Ltd. Announces the Appointment of Murray Miller to Its Board of Directors as an Independent Director

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.710225 million.